Lee Spencer
Psychiatry · Dallas, TXNPI 1386887917
Payments from drug & device makers
Across 380 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$773
- AbbVie$682
- Lundbeck LLC$613
- Alkermes, Inc.$595
- Johnson & Johnson$561
- Bausch Health US, LLC$559
- plus $3K from 20 others
What the payments were for
- Food & beverage$7,142100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $773 |
| AbbVie(2 entities) | 47 | $682 |
| Lundbeck LLC | 32 | $613 |
| Alkermes, Inc. | 30 | $595 |
| Johnson & Johnson | 28 | $561 |
| Bausch Health US, LLC | 38 | $559 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $526 |
| Otsuka America Pharmaceutical, Inc. | 21 | $417 |
| Neurocrine Biosciences, Inc. | 18 | $409 |
| Vanda Pharmaceuticals Inc. | 10 | $290 |
| Supernus Pharmaceuticals, Inc. | 19 | $272 |
| Tris Pharma Inc | 13 | $270 |
| Sunovion Pharmaceuticals Inc. | 14 | $198 |
| Indivior Inc. | 4 | $172 |
| Avanir Pharmaceuticals, Inc. | 8 | $144 |
| Axsome Therapeutics, Inc. | 6 | $135 |
| Idorsia Pharmaceuticals US Inc | 7 | $120 |
| Merck | 7 | $118 |
| Shire North American Group Inc | 4 | $76 |
| Neos Therapeutics, LP | 3 | $56 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| Corium, LLC | 1 | $33 |
| Adlon Therapeutics L.p. | 1 | $26 |
| Ironshore Pharmaceuticals Inc. | 1 | $25 |
| Vertical Pharmaceuticals, LLC | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUBLOCADE$104
How this compares
$7,142 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelsomraSuvorexant | 25 | $10,561 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 17 | $2,944 |
| Buspirone Hcl | 12 | $770 |
| Bupropion XlBupropion Hcl | 19 | $557 |
| Gabapentin | 25 | $531 |
| Quetiapine Fumarate | 21 | $433 |
| Mirtazapine | 13 | $363 |
| Trazodone Hcl | 32 | $358 |
| Escitalopram Oxalate | 18 | $318 |
| Lamotrigine | 16 | $135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckBelsomra | $118 | $10,56125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Dallas
- Scott BartleyDallas$42.7M
- Darin OkudaDallas$14.7M
- Michael DowningDallas$7.6M
- John PascoeDallas$2.3M
- Madhukar TrivediDallas$2.1M
- Manish JhaDallas$1.3M
- Mary KnesevichDallas$1.2M
- Seema GuptaDallas$1.2M
- Eric WilliamsDallas$976K
- Joel HolinerDallas$948K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.